title: Ezogabine (KCNQ2/3 channel opener) prevents delayed activation of meningeal nociceptors if given before but not after the occurrence of cortical spreading depression.
abstract: We proposed recently that induction of delayed activation of trigeminovascular neurons by cortical spreading depression (CSD) can explain the delayed onset of headache after the migraine aura ("aura"). This prompted us to search for ways to block the neuronal activation by CSD - a preclinical correlate of an attempt to find a drug that can block the initiation of headache when administered shortly after onset of aura (i.e., preemptively). Because migraine headache and epileptic seizures are comorbid chronic neurological disorders characterized by hyperexcitable brain networks, we began the search for such goal with an M-type potassium channel opener. We opted to use ezogabine, recently approved by the FDA as adjunctive treatment of partial onset seizures in adults, because it is a selective KCNQ2/3 channel opener. When CSD was induced before ezogabine injection (8.25 mg/kg, i.p.), 40% (6/15) of the units doubled their firing rate about 45 min later for about 95 min. Similarly, when CSD was induced before vehicle was injected (4% DMSO, 0.5% methylcellulose), 50% (3/6) of the units doubled their firing rate about 30 min later for about 120 min. When CSD was triggered 1h after ezogabine injection, it activated only 8% of the units. By itself, ezogabine injection resulted in a 30% attenuation of ongoing firing in all 10 control units. Thus, activation of KCNQ2/3 channels during the aura is unlikely to preempt the onset of headache but may reduce the incidence of migraine if given during prodromes that precede the headache by hours. Given the mechanistic similarities between migraine aura and epileptic seizures, it may be worthwhile to determine whether preemptive administration of ezogabine can prevent oncoming seizures in patients whose warning signs precede their seizures by more than an hour.
authors.affiliation: Department of Anesthesia and Critical Care, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
authors.forename: XiChun
authors.initials: X
authors.lastname: Zhang
authors.forename: Moshe
authors.initials: M
authors.lastname: Jakubowski
authors.forename: Catherine
authors.initials: C
authors.lastname: Buettner
authors.forename: Vanessa
authors.initials: V
authors.lastname: Kainz
authors.forename: Michael
authors.initials: M
authors.lastname: Gold
authors.forename: Rami
authors.initials: R
authors.lastname: Burstein
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D000927:Anticonvulsants / Q000008:administration & dosage*; D002219:Carbamates / Q000008:administration & dosage*; D013181:Cortical Spreading Depression / Q000187:drug effects* / Q000502:physiology; D004334:Drug Administration Schedule; D008297:Male; D009619:Nociceptors / Q000187:drug effects*; D010147:Pain Measurement; D010655:Phenylenediamines / Q000008:administration & dosage*; D010812:Physical Stimulation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013268:Stimulation, Chemical; D013997:Time Factors; D012668:Trigeminal Ganglion / Q000166:cytology*
chemical_list: D000927:Anticonvulsants; D002219:Carbamates; D010655:Phenylenediamines; C101866:ezogabine
references.citation: Epilepsy Res. 2011 Sep;96(1-2):176-9
references.pmid: 21665439
references.citation: Cell Mol Life Sci. 2007 Aug;64(16):2090-103
references.pmid: 17514356
references.citation: Mol Pharmacol. 2000 Sep;58(3):591-600
references.pmid: 10953053
references.citation: Arch Neurol. 1999 May;56(5):548-54
references.pmid: 10328249
references.citation: Headache. 2012 Jun;52(6):930-45
references.pmid: 22671714
references.citation: Curr Top Med Chem. 2005;5(1):3-14
references.pmid: 15638774
references.citation: J Neurophysiol. 2009 Jun;101(6):3126-34
references.pmid: 19339455
references.citation: J Neurosci. 2001 Jul 1;21(13):4609-24
references.pmid: 11425889
references.citation: Ann Neurol. 2011 May;69(5):855-65
references.pmid: 21416489
references.citation: J Pharmacol Exp Ther. 1999 Mar;288(3):960-8
references.pmid: 10027832
references.citation: Epilepsia. 2005 Dec;46(12):1955-62
references.pmid: 16393162
references.citation: J Neurosci. 2001 Aug 1;21(15):5535-45
references.pmid: 11466425
references.citation: Eur J Pharmacol. 1997 Oct 8;336(2-3):243-9
references.pmid: 9384239
references.citation: J Clin Pharmacol. 2002 Feb;42(2):175-82
references.pmid: 11831540
references.citation: Neurology. 2007 Apr 10;68(15):1197-204
references.pmid: 17420403
references.citation: Nature. 1996 Dec 12;384(6609):560-4
references.pmid: 8955268
references.citation: Epilepsia. 2012 Mar;53(3):425-36
references.pmid: 22221318
references.citation: Seizure. 2005 Mar;14(2):100-5
references.pmid: 15694562
references.citation: Funct Neurol. 1986 Oct-Dec;1(4):363-6
references.pmid: 3609866
references.citation: Lancet Neurol. 2006 Feb;5(2):148-157
references.pmid: 16426991
references.citation: J Neurosci. 2010 Jun 30;30(26):8807-14
references.pmid: 20592202
references.citation: Neurotherapeutics. 2007 Apr;4(2):184-98
references.pmid: 17395128
references.citation: Annu Rev Physiol. 1997;59:483-504
references.pmid: 9074774
references.citation: Cephalalgia. 2007 Dec;27(12):1427-39
references.pmid: 18034686
references.citation: Neurology. 1996 Oct;47(4):918-24
references.pmid: 8857719
references.citation: Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4687-92
references.pmid: 11287655
references.citation: J Neurophysiol. 1975 Jul;38(4):822-41
references.pmid: 1159468
references.citation: Neurol Clin. 1997 Feb;15(1):107-14
references.pmid: 9058399
references.citation: JAMA. 2004 Feb 25;291(8):965-73
references.pmid: 14982912
references.citation: Epilepsia. 2000;41(S1):21-4
references.pmid: 10768295
references.citation: Brain. 1984 Jun;107 ( Pt 2):447-61
references.pmid: 6609739
references.citation: Headache. 1999 Jul-Aug;39(7):469-76
references.pmid: 11279929
references.citation: Mol Pharmacol. 2000 Aug;58(2):253-62
references.pmid: 10908292
references.citation: J Neurosci Res. 2005 Jun 1;80(5):715-26
references.pmid: 15880382
references.citation: Annu Rev Physiol. 1999;61:835-56
references.pmid: 10099712
references.citation: J Headache Pain. 2011 Jun;12(3):289-94
references.pmid: 21360158
references.citation: Brain Res. 1993 May 7;610(2):276-82
references.pmid: 8100471
references.citation: Cephalalgia. 2007 Dec;27(12):1442-53
references.pmid: 18034688
references.citation: J Neurosci. 1994 Nov;14(11 Pt 2):7087-98
references.pmid: 7965100
references.citation: Neurochem Int. 2000 Aug-Sep;37(2-3):103-10
references.pmid: 10812195
references.citation: J Neurosci. 2010 Jun 9;30(23):7878-88
references.pmid: 20534836
references.citation: J Neurophysiol. 1947 Nov;10(6):409-14
references.pmid: 20268874
references.citation: Eur J Pharmacol. 2003 Mar 19;464(2-3):95-100
references.pmid: 12620500
references.citation: Epilepsy Res. 2006 Jul;70(1):83-8
references.pmid: 16531010
references.citation: Brain. 1994 Feb;117 ( Pt 1):199-210
references.pmid: 7908596
references.citation: Neurology. 2002 Jun 11;58(11):1652-9
references.pmid: 12058094
references.citation: J Neurosci. 2003 Aug 6;23(18):7227-36
references.pmid: 12904483
references.citation: Ann Neurol. 2005 Nov;58(5):698-705
references.pmid: 16240341
references.citation: Nature. 1999 Jun 24;399(6738 Suppl):A15-22
references.pmid: 10392576
references.citation: Science. 1998 Dec 4;282(5395):1890-3
references.pmid: 9836639
references.citation: Lancet Neurol. 2009 Jul;8(7):679-90
references.pmid: 19539239
references.citation: Epilepsia. 1999 Nov;40(11):1471-83
references.pmid: 10565572